Infigratinib 0.064 mg/kg (DrugBank: Infigratinib)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 276 | Achondroplasia | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04265651 (ClinicalTrials.gov) | March 10, 2020 | 29/1/2020 | Study of Infigratinib in Children With Achondroplasia | Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2 | Achondroplasia | Drug: Infigratinib 0.016 mg/kg;Drug: Infigratinib 0.032 mg/kg;Drug: Infigratinib 0.064 mg/kg;Drug: Infigratinib 0.128 mg/kg | QED Therapeutics, Inc. | NULL | Recruiting | 3 Years | 11 Years | All | 60 | Phase 2 | Australia;Spain;United Kingdom |